Anvances in research on Raf kinase inhibitory protein in common digestive system malignant tumors
10.3781/j.issn.1000-7431.2013.04.015
- Author:
Min YU
1
Author Information
1. Department of Cestroenterology
- Publication Type:Journal Article
- Keywords:
Digestive system neoplasms;
MAP kinase signaling system;
Phosphatidylethanolamine-binding protein;
Raf kinases
- From:
Tumor
2013;33(4):378-381
- CountryChina
- Language:Chinese
-
Abstract:
RKIP (Raf kinase inhibitor protein) is a member of PEBP (phosphatidylethanolamine-binding protein) family, which plays a pivotal modulatory role in MAPK (mitogen-activated protein kinase), CPCR (G-protein-coupled receptor) and NF-KB (nuclear factor-kappa B) signaling transduction pathways. In recent years, many studies reported that RKIP expression is weakened or lost in a series of malignant tumors such as prostate cancer, breast cancer and melanoma. RKIP may also play an important role in inhibition of tumor metastasis via inhibition of cell invasion and tumor angiogenesis. Recently, many experiments revealed that RKIP which is a metastasis-suppressor gene participates in the suppression of metastasis in a variety of digestive system malignant tumors and it will become a new target for prevention and control of digestive system cancer. In this article, the advances of research on RKIP in common digestive system malignant tumors were reviewed. Copyright © 2013 by TUMOR.
